"Novo Nordisk (NVO) recently received accelerated FDA approval for its weight-loss drug Wegovy to treat liver disease, which could serve as a significant growth catalyst. However, the company is facing risks from a class action lawsuit and a moderate average sentiment score of 0.27, indicating cautious investor sentiment."